Lisa A. Conte

Insider Reports History

Location
213 East Grand Avenue, South San Francisco, CA
Signature
/s/ Lisa A Conte
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Lisa A. Conte:

Stock Role Class Num Shares Value Price $ Report Date Ownership
Jaguar Health, Inc. CEO and President, Director Convertible Promissory Note 9.46K $473M $50,000.00 Jun 24, 2025 Direct
Jaguar Health, Inc. CEO and President, Director Common Stock 666 $7.99K $11.99 May 17, 2025 Direct
Jaguar Health, Inc. CEO and President, Director Restricted stock units 0 $0 $0.03 May 17, 2025 Direct
Jaguar Health, Inc. CEO and President, Director Stock option (right to buy) 132K Oct 8, 2024 Direct
Jaguar Health, Inc. CEO and President, Director Warrant to Purchase Common Stock 9K Jun 24, 2025 Direct

Insider Reports Filed by Lisa A. Conte

Symbol Company Period Transactions Value $ Form Type Date Filed Role
JAGX Jaguar Health, Inc. Jun 24, 2025 3 $23.1M 4 Jun 26, 2025 CEO and President, Director
JAGX Jaguar Health, Inc. May 17, 2025 2 $0 4 May 20, 2025 CEO and President, Director
JAGX Jaguar Health, Inc. Mar 31, 2025 2 $450M 4 Apr 2, 2025 CEO and President, Director
JAGX Jaguar Health, Inc. Oct 8, 2024 2 $0 4 Oct 10, 2024 Chief Executive Officer and President, Director
JAGX Jaguar Health, Inc. May 17, 2024 2 $0 4 May 21, 2024 CEO and President, Director
JAGX Jaguar Health, Inc. Apr 5, 2024 2 $0 4 Apr 17, 2024 CEO and President, Director
JAGX Jaguar Health, Inc. Aug 14, 2023 1 $0 4 Aug 14, 2023 CEO and President, Director
JAGX Jaguar Health, Inc. May 17, 2023 2 $0 4 May 19, 2023 CEO and President, Director
JAGX Jaguar Health, Inc. Apr 5, 2023 2 $0 4 Apr 20, 2023 CEO and President, Director
JAGX Jaguar Health, Inc. Dec 27, 2022 1 $0 4 Dec 28, 2022 CEO and President, Director
JAGX Jaguar Health, Inc. Apr 5, 2022 2 $0 4 Apr 6, 2022 CEO and President, Director
JAGX Jaguar Health, Inc. Sep 13, 2021 3 $20K 4 Mar 30, 2022 CEO and President, Director